Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products, as well as medical supplies. The company also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; offers pharmacy management services to hospitals; operates pharmacies, including pharmacies in community health centers; and repackages generic pharmaceuticals and over-the-counter healthcare products. In addition, it manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compression solution, incontinence, nutritional delivery, and wound care products; single-use surgical drapes, gowns, and apparel products; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. Further, the company distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. Additionally, it manufactures, prepares, delivers, and distributes radiopharmaceuticals and related treatments; and optimizes direct shipments through integrated technology solutions. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Financial Triumph | Cardinal Health surpasses Q1 expectations, raising FY25 EPS guidance amid strong pharmaceutical and specialty segment performance |
Strategic Expansion | Acquisition of Integrated Oncology Network for $1.115B signals shift to offensive growth strategy in community oncology market |
Segment Dynamics | Explore the contrasting performances of Cardinal Health's divisions, with pharmaceutical success offsetting challenges in medical products |
Market Positioning | Analysts set price targets ranging from $107 to $133, reflecting confidence in Cardinal Health's growth potential and strategic direction |
Metrics to compare | CAH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAHPeersSector | |
---|---|---|---|---|
P/E Ratio | 25.4x | −1.5x | −0.5x | |
PEG Ratio | 0.16 | 0.13 | 0.00 | |
Price/Book | −13.4x | 0.7x | 2.6x | |
Price / LTM Sales | 0.2x | 0.8x | 3.0x | |
Upside (Analyst Target) | 8.8% | 53.3% | 51.5% | |
Fair Value Upside | Unlock | 30.5% | 9.4% | Unlock |